news

CUPERTINO, Calif., Oct. 22, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that Pfizer Inc. (NYSE: PFE) has stated that, having achieved technical milestones related to manufacturing, they will continue the development program for REMOXY® (oxycodone) Extended-Release Capsules CII. Following guidance received from the U.S. Food and Drug Administration (FDA) earlier this year, Pfizer announced […]

Jay Shepard to join the Board effective September 26, 2013 Michael Casey to retire from the Board effective December 31, 2013 CUPERTINO, Calif., Sept. 27, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Jay Shepard will join its Board of Directors effective September 26, 2013.  Separately, Michael Casey has made the decision to

CUPERTINO, Calif., Sept. 3, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at three upcoming healthcare conferences. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) James E. Brown, President and CEO, will present at the Rodman and Renshaw Conference on Monday, September 9 at 10:00 a.m. Eastern time.  The conference is being held at the

CUPERTINO, Calif., Aug. 5, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2013. Total revenues were $3.9 million for the three months ended June 30, 2013 as compared to $4.8 million for the three months ended June 30, 2012.  Net loss for the three months ended June

CUPERTINO, Calif., Aug. 1, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it and its collaborator Orient PHARMA Co., Ltd., a diversified multinational pharmaceutical, healthcare and consumer products company with headquarters in Taiwan, have selected a lead formulation for the lead program in DURECT’s ORADUR-ADHD program, ORADUR-Methylphenidate.  This lead formulation was chosen based

CUPERTINO, Calif., July 26, 2013 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 5, 2013 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A

CUPERTINO, Calif., June 20, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that the New Drug Application (NDA) for the investigational product POSIDUR (SABER-Bupivacaine) has been accepted by the U.S. Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review. POSIDUR is a post-operative pain relief depot that

CUPERTINO, Calif., May 10, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Pfizer has provided an update on Remoxy as part of their Form 10-Q filing.  Pfizer’s disclosure is as follows: “In 2005, King Pharmaceuticals, Inc. (King) entered into an agreement with Pain Therapeutics, Inc. (PT) to develop and commercialize Remoxy.  In August

CUPERTINO, Calif., May 2, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the first quarter of 2013. Total revenues were $4.2 million and net loss was $5.2 million for the three months ended March 31, 2013.  For comparison, total GAAP revenue was $41.2 million and net income was $30.8 million for

CUPERTINO, Calif., April 24, 2013 /PRNewswire/ — In conjunction with DURECT Corporation‘s (Nasdaq: DRRX) first quarter 2013 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, May 2, 2013 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live